TITLE

Prediction of mortality of patients with suspected heart failure by brain natriuretic peptide concentrations > 100 pg/ ml: comparison of a clinical model with brain natriuretic peptide concentrations

AUTHOR(S)
Kellett, J.
PUB. DATE
October 2006
SOURCE
Heart;Oct2006, Vol. 92 Issue 10, p1512
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a research on the prediction of heart failure mortality within 30 days by brain natriuretic peptide (BNP) concentrations as compared with the model used by D.S. Lee and colleagues in their study which was published in a 2003 issue of the "Journal of the American Medical Association." The study found that BNP concentration and the model used by Lee accurately both predict mortality.
ACCESSION #
22838819

 

Related Articles

  • BATTLESCARRED: NT-proBNP-guided therapy improved mortality in older patients with chronic HF.  // Cardiology Today;Feb2010, Vol. 13 Issue 2, p23 

    The article discusses the BATTLESCARRED research on the efficacy of a hormone-guided treatment strategy guided by N-terminal pro-B-type natriuretic peptide levels in reducing mortality in patients aged 75 years and older with chronic heart failure (HF), with a reference to a study by J....

  • Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Xue, Yang; Clopton, Paul; Peacock, William F.; Maisel, Alan S. // European Journal of Heart Failure;Jan2011, Vol. 13 Issue 1, p37 

    Aims The aim of this study was to evaluate the prognostic utility of small troponin I (TnI) elevations, serial TnI measurements, and the combination of TnI and brain natriuretic peptide (BNP) in patients with decompensated heart failure (HF). Methods and results One hundred and forty-four...

  • N-terminal brain natriuretic peptide is predictive of death after cardiac transplantation. Gardner, R. S.; Chong, K. S.; Murday, A. J.; Morton, J. J.; McDonagh, T. A. // Heart;Jan2006, Vol. 92 Issue 1, p121 

    The article presents information on a study that evaluates the short term prognostic ability of N-terminal portion of pro-brain natriuretic peptide (NT-proBNP) in patients after cardiac transplantation. Brain natriuretic peptide (BNP) and the NT-proBNP are now well established diagnostic and...

  • QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure. Breidthardt, Tobias; Christ, Michael; Matti, Miriam; Schrafl, Delia; Laule, Kirsten; Noveanu, Markus; Boldanova, Tujana; Klima, Theresia; Hochholzer, Willibald; Perruchoud, André P.; Mueller, Christian // Heart;Sep2007, Vol. 93 Issue 9, p1093 

    Objectives: To quantify the prognostic utility of QRS and QTc interval prolongation in patients presenting with acute destabilised heart failure (ADHF) to the emergency department (ED). Design: Prospective cohort study among patients enrolled in the B-Type Natriuretic Peptide for Acute Shortness...

  • Examining the uses of BNP testing in the outpatient setting. Harrison, Alex // Patient Care;Aug2005, Vol. 39 Issue 8, p38 

    Focuses on an investigation launched to explore the use of B-natriuretic peptide (BNP) values in the outpatient setting. Association of the perceived severity of congestive heart failure (CHF) with BNP levels according to the Rapid Emergency Department Heart Failure Outpatient Trial; Potential...

  • Nesiritide: A Review of its Use in Acute Decompensated Heart Failure. Keating, G.M.; Goa, K.L. // Drugs;2003, Vol. 63 Issue 1, p47 

    Nesiritide (Natrecor) is a recombinant form of human B-type (brain) natriuretic peptide that has beneficial vasodilatory, natriuretic, diuretic and neurohormonal effects. The drug is administered intravenously for the management of patients with decompensated congestive heart failure (CHF). In...

  • NILE PURSUES POST-ACUTE INDICATION IN HEART FAILURE.  // Biotech Business;Apr2011, Vol. 24 Issue 4, p8 

    The article reports on the plan of U.S.-based Nile Therapeutics Inc. to pursue a post-acute indication in heart failure. The company seeks to develop the natriuretic peptide cenderitide as an outpatient therapy for patients with acutely decompensated heart failure (ADHF). Sustained cardiac and...

  • Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction�. Hoekstra, Tialda; Lesman-Leegte, Ivonne; van Veldhuisen, Dirk J.; Sanderman, Robbert; Jaarsma, Tiny // European Journal of Heart Failure;Sep2011, Vol. 13 Issue 9, p1013 

    Aims To compare quality of life (QoL) in heart failure (HF) patients with preserved ejection fraction (HF-PEF) and HF patients with reduced ejection fraction (HF-REF) in a well-defined HF population. Methods and results Patients with HF-PEF [left ventricular ejection fraction (LVEF) =40%] were...

  • The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement. Sedlak, Tara L.; Chandavimol, Mann; Calleja, Anna; Clark, Catherine; Edmonds, Margaret; Pu, Aihua; Humphries, Karin H.; Ignaszewski, Andrew // Open Cardiovascular Medicine Journal;2008, Vol. 2, p36 

    Background: The value of routine aminoterminal pro type B natriuretic peptide (NT-proBNP) measurements in outpatient clinics remains unknown. Objectives: We sought to determine the accuracy with which heart failure (HF) specialists can predict NT-proBNP levels in HF outpatients based on clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics